Harrow Health, Inc. (HROW)
NASDAQ: HROW · IEX Real-Time Price · USD
10.53
+0.53 (5.30%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Harrow Health Revenue
In the year 2023, Harrow Health had annual revenue of $130.19M with 46.95% growth. Revenue in the quarter ending December 31, 2023 was $36.36M with 78.83% year-over-year growth.
Revenue (ttm)
$130.19M
Revenue Growth
+46.95%
P/S Ratio
2.86
Revenue / Employee
$413,311
Employees
315
Market Cap
372.37M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
Dec 31, 2018 | 41.37M | 14.60M | 54.52% |
Dec 31, 2017 | 26.77M | 6.83M | 34.26% |
Dec 31, 2016 | 19.94M | 10.23M | 105.25% |
Dec 31, 2015 | 9.72M | 8.06M | 485.30% |
Dec 31, 2014 | 1.66M | 1.65M | 16,500.00% |
Dec 31, 2013 | 10.00K | -90.00K | -90.00% |
Dec 31, 2012 | 100.00K | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DocGo | 624.29M |
Amarin Corporation | 306.91M |
Tactile Systems Technology | 274.42M |
Revance Therapeutics | 234.04M |
Pacific Biosciences of California | 200.52M |
Zynex | 184.32M |
Surmodics | 138.20M |
Esperion Therapeutics | 116.33M |
HROW News
- 2 days ago - Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 - Business Wire
- 25 days ago - Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing - Business Wire
- 5 weeks ago - Harrow Announces Fourth Quarter and Year-End 2023 Financial Results - Business Wire
- 7 weeks ago - Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 - Business Wire
- 2 months ago - Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products - Business Wire
- 3 months ago - Harrow Announces New Appointments to its Board of Directors - Business Wire
- 3 months ago - Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease - Business Wire
- 4 months ago - Harrow Partners with Leading Healthcare Market Access Technology Platforms - Business Wire